Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily… - The Lancet, 2019 - thelancet.com
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based …

M Falcaro, A Castañon, B Ndlela, M Checchi, K Soldan… - The Lancet, 2021 - thelancet.com
Background Human papillomavirus (HPV) immunisation with a bivalent vaccine (Cervarix)
was introduced in England, UK, in Sept 1, 2008: routine vaccination was offered to girls …

HPV vaccination and cancer prevention

A Athanasiou, S Bowden, M Paraskevaidi… - Best Practice & …, 2020 - Elsevier
Prophylactic vaccines have been found to be highly effective in preventing infection and pre-
invasive and invasive cervical, vulvovaginal and anal disease caused by the vaccine types …

Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)

M Kyrgiou, M Arbyn, C Bergeron, FX Bosch… - British journal of …, 2020 - nature.com
This paper summarises the position of ESGO and EFC on cervical screening based on
existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as …

Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence

DR Brown, EA Joura, GP Yen, S Kothari… - Vaccine, 2021 - Elsevier
Background The extent of cross-protection provided by currently licensed bivalent and
quadrivalent HPV vaccines versus direct protection against HPV 31-, 33-, 45-, 52-, and 58 …

The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening …

M Rebolj, F Pesola, C Mathews, D Mesher… - British journal of …, 2022 - nature.com
Abstract Background In England, bivalent vaccination (Cervarix) against high-risk human
papillomavirus (HR-HPV) genotypes 16/18 was offered in a population-based catch-up …

[HTML][HTML] Human papillomavirus vaccination: The ESGO–EFC position paper of the European society of Gynaecologic Oncology and the European Federation for …

EA Joura, M Kyrgiou, FX Bosch, V Kesic… - European Journal of …, 2019 - Elsevier
Vaccines against human papillomavirus (HPV) are available in Europe since 2006. They
have been highly effective in preventing infection and disease caused by the vaccine types …

It is time for universal HPV vaccination

G Prue, P Baker, D Graham, C Nutting, P Greenhouse… - The Lancet, 2018 - thelancet.com
Potential adverse consequences of physical overexertion have been periodic ally debated
since the legend of Pheidippides, who was said to have collapsed and died after running 26 …

Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination

LE Markowitz, AL Naleway, RM Lewis, B Crane… - Vaccine, 2019 - Elsevier
Background Human papillomavirus (HPV) vaccine has been recommended in the United
States since 2006 for routine vaccination of girls at age 11–12 years and through age 26 …